MRCP2-0950

You are evaluating a 60-year-old man who has just commenced treatment for urological cancer with Nivolumab (Opdivo), a type of checkpoint inhibitor. He has been receiving treatment for a month and has not experienced any adverse effects thus far. He is curious about what he can anticipate from this therapy.

What is the most prevalent side effect that this patient is likely to encounter?